Evidence map›Paper›PMID 25038432›Full record

ArticleGastroenterology2014

Signatures of protective memory immune responses during hepatitis C virus reinfection.

Mohamed S Abdel-Hakeem, Nathalie Bédard, Donald Murphy, Julie Bruneau, Naglaa H Shoukry

Open access · bronzeAbstract read
In one paragraph

Article in Gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 62 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Observational
  4. Functional Antigen-Specific CD8 TEuropean journal of immunology · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Immunological Monitoring in Hepatitis C Virus Controlled Human Infection Model.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Expansion of Unique Hepatitis C Virus-Specific Public CD8Journal of immunology (Baltimore, Md. : 1950) · 2021
    Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Mohamed S Abdel-HakeemCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada; Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo, Egypt; Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, Québec, Canada.
Nathalie BédardCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada.
Donald MurphyInstitut National de Santé Publique du Québec, Laboratoire de Santé Publique du Québec (LSPQ), Sainte-Anne-de-Bellevue, Québec, Canada.
Julie BruneauCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada; Département de médecine familiale et de médecine d'urgence, Université de Montréal, Montréal, Québec, Canada.
Naglaa H ShoukryCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada; Département de médecine, Université de Montréal, Montréal, Québec, Canada. Electronic address: naglaa.shoukry@umontreal.ca.
Centre Hospitalier de l’Université de Montréal · CACairo University · EGInstitut National de Santé Publique du Québec · CAUniversité de Montréal · CA

Funding

International Collaborative of prospective studies of HIV and Hepatitis in IDUR01DA031056 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2011 to 2015
$2.2M
CIHRNIDA NIH HHS R01 DA031056NIDA NIH HHS R01DA031056
6 · The paper itself

Abstract

BACKGROUND &

aimsDevelopment of a vaccine against hepatitis C virus (HCV) has been hindered by our limited understanding of immune correlates of protection during real-life exposure to the virus. We studied the immune response during HCV reinfection.

methodsWe analyzed blood samples from participants in the Montreal Acute Hepatitis C Injection Drug User Cohort Study who were reinfected with HCV from 2009 to 2012. Five patients spontaneously resolved their second infection and 4 developed chronic infections. We monitored the phenotypic and functional dynamics of HCV-specific memory T cell responses in all subjects during natural re-exposure and re-infection.

resultsPopulations of CD4(+) and CD8(+) T cells with HCV-specific polyfunctional memory were expanded in all 5 individuals who resolved 2 successive HCV infections. We detected CD127(hi) HCV-specific memory CD8(+) T cells before reinfection regardless of a subject's ability to clear subsequent infections. Protection against viral persistence was associated with the expansion of a CD127(neg), PD1(lo) effector memory T cells at the peak of the response. We also observed broadening of T-cell response, indicating generation of de novo T-cell responses. The 4 individuals who failed to clear their subsequent infection had limited expansion of HCV-specific CD4(+) and CD8(+) memory T cells and expressed variable levels of the exhaustion marker PD1 on HCV-specific CD8(+) T cells. Dominant epitope regions of HCV strains isolated from patients with persistent reinfection had sequence variations that were not recognized by the pre-existing memory T cells.

conclusionsProtection from persistent HCV reinfection depends on the magnitude, breadth, and quality of the HCV-specific memory T-cell response. Sequence homology among viruses and ability of T cells to recognize multiple strains of HCV are critical determinants of protective memory.

Indexed as

Immunologic MemoryAntigens, ViralBiomarkersCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell ProliferationEpitopes, T-LymphocyteHepacivirusHepatitis CHumansImmunophenotypingInterleukin-7 Receptor alpha SubunitLymphocyte ActivationPhenotypeProgrammed Cell Death 1 ReceptorQuebecAntigens, ViralBiomarkersEpitopes, T-LymphocyteInterleukin-7 Receptor alpha SubunitPDCD1 protein, humanProgrammed Cell Death 1 ReceptorRNA, ViralCytokinesImmune RegulationProtective ImmunityViral Infection

Identifiers

PMID25038432
PMCPMC4170061
OpenAlexW2151557253

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.